Bits x Bites
Deal focus: GPs go big on China biosynthesis
Advances in synthetic biology and China’s carbon-neutral ambitions have prompted investors to re-examine bio-manufacturing plays. Mojia Biotech is among the beneficiaries
Advances in synthetic biology and China’s carbon-neutral ambitions have prompted investors to re-examine bio-manufacturing plays. Mojia Biotech is among the beneficiaries